News | June 24, 2022
Silo Pharma expands license agreement and patent portfolio
Silo enters into commercial evaluation license agreement for next generation liposomes
Silo enters into commercial evaluation license agreement for next generation liposomes
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Gilman will be responsible for all business development and portfolio strategy efforts globally.
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
_256_384.png)
Thermo Scientific Direct Mass Technology mode augments Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers with charge detection capabilities
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Tislelizumab is now approved in nine indications in China
New Director supports NASDAQ rule on diversity
Subscribe To Our Newsletter & Stay Updated
